New York Attorney General James Secures Agreement With Insulin Maker Novo Nordisk To Cap Insulin Prices For Uninsured New Yorkers; Novo Nordisk Agrees To Cap Insulin Price At $35 Per Monthly Prescription For Uninsured New Yorkers For 5 Years
Portfolio Pulse from Benzinga Newsdesk
New York Attorney General has secured an agreement with insulin manufacturer Novo Nordisk to cap insulin prices for uninsured New Yorkers. The agreement stipulates a cap on insulin price at $35 per monthly prescription for uninsured New Yorkers for the next 5 years.

September 08, 2023 | 6:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novo Nordisk has agreed to cap insulin prices for uninsured New Yorkers, which may impact its revenue in the short term.
Novo Nordisk's agreement to cap insulin prices for uninsured New Yorkers at $35 per monthly prescription for the next 5 years could potentially reduce its revenue from this segment. This is because the company may not be able to increase prices in response to rising costs or inflation, which could squeeze margins. However, the impact may be mitigated if the price cap leads to increased volume of sales.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100